Santiago Demajo

Santiago Demajo

Auto-generated profile, based on publicly available information

Santiago Demajo

Pompeu Fabra University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
ADAndreas Doll
Andreas Doll
MPMiguel Abal Posada
Miguel Abal Posada
MRM. Rigau
M. Rigau
MMM. Monge
M. Monge
MGM. Gonzalez
M. Gonzalez
JRJ. Reventós
J. Reventós

22 December 2010 in Nature
Verified
Journal Article
Closed access
HRHolger Richly
Holger Richly
LRLuciana Rocha-Viegas
Luciana Rocha-Viegas
JRJoana Domingues Ribeiro
Joana Domingues Ribeiro
SDSantiago Demajo
Santiago Demajo
GGGunes Gundem
Gunes Gundem
Luciano Di CroceLuciano Di Croce
Luciano Di Croce

26 July 2018 in Blood
Verified
Journal Article
Open access
PDF file
GCGuillem Clot
Guillem Clot
PJPedro Jares
Pedro Jares
EGEva Giné
Eva Giné
ANAlba Navarro
Alba Navarro
CRCristina Royo
Cristina Royo
ECElías Campo
Elías Campo
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic non-nodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. Herein, we describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples. We trained a 16 gene assay (L-MCL16 Assay) on the NanoString platform using 19 purified leukemic samples. The locked assay was applied to an independent cohort of 70 MCL patients with leukemic presentation. The assay assigned 37% of cases to nnMCL and 56% to cMCL. nnMCL and cMCL differed in nodal presentation, LDH, IGHV mutational status, management options, genomic complexity and CDKN2A/ATM deletions, but the proportion with 17p/TP53 aberrations were similar in both subgroups. Sequential samples showed that assay prediction was stable over time. nnMCL had a better overall survival (OS) than cMCL (3-year OS 92% vs. 69%, P=0.006) from the time of diagnosis and longer time-to-treatment (TTT). Genomic complexity and TP53/CDKN2A aberrations predicted for shorter OS in the whole series and cMCL, whereas only genomic complexity was associated with shorter TTT and OS in nnMCL. In conclusion, the newly developed assay robustly recognizes the two molecular subtypes of MCL in leukemic samples. Its combination with genetic alterations improves the prognostic evaluation and may provide useful biological information for management decisions. Key points A new molecular assay identifies conventional and leukemic non-nodal MCL differing in clinico-biological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.

13 October 2011 in Epigenomics
Verified
Journal Article
Closed access
MLMartin Lange
Martin Lange
SDSantiago Demajo
Santiago Demajo
PJPayal Jain
Payal Jain
Luciano Di CroceLuciano Di Croce
Luciano Di Croce
The introduction of new methods for genome-wide analyses of the chromatin state, together with the power of refined techniques for mass spectrometry and biochemistry, has provided an unprecedented ...

23 October 2011 in Nature Cell Biology
Verified
Journal Article
Closed access
IUIris Uribesalgo
Iris Uribesalgo
MBMarcus Buschbeck
Marcus Buschbeck
AGArantxa Gutiérrez
Arantxa Gutiérrez
STSophia Teichmann
Sophia Teichmann
SDSantiago Demajo
Santiago Demajo
Luciano Di CroceLuciano Di Croce
Luciano Di Croce

20 August 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RARobert Albero
Robert Albero
AEAnna Enjuanes
Anna Enjuanes
SDSantiago Demajo
Santiago Demajo
GCGiancarlo Castellano
Giancarlo Castellano
MPMagda Pinyol
Magda Pinyol
PJPedro Jares
Pedro Jares
Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of most actively transcribed genes, and the promoter occupancy positively correlated with the transcriptional output of targeted genes. Despite this association, the overexpression of cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was proportional to cyclin D1 levels. This cyclin D1–dependent global transcriptional downregulation was associated with a reduced nascent transcription and an accumulation of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1. Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index. This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential of targeting the transcriptional machinery in cyclin D1–overexpressing tumors.